Print

Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announce Analyses from OMONTYS® (peginesatide) Injection Phase 3 Dialysis Studies Presented at 2012 American Society of Nephrology Meeting  
11/2/2012 8:25:06 AM

PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS® (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients. The analyses, which explore intravenous (IV) iron utilization in U.S. patients in the EMERALD Phase 3 studies, were presented in an oral session at the 2012 American Society of Nephrology (ASN) Kidney Week meeting.
//-->